Advertisement

NLS Actavis

Acquisition - March 15, 2017

The new Teva grows stronger – in Norway

In August last year Teva completed its acquisition of Actavis Generics and the new Teva in Norway will be among the 15 largest companies in the country. The new company will be named Teva and will be located at Teva’s facilities in Hagaløkkveien in Asker. Employees from Actavis moved in with the Teva team in […]

Acquisition - March 12, 2015

AstraZeneca Buys More Respiratory Business

AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]

Acquisition - February 18, 2015

AstraZeneca to Acquire Actavis’ Branded Respiratory Side in U.S., Canada

AstraZeneca plans to acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold.  When the transaction is finalized, AstraZeneca will own the development and commercial rights in the US and Canada to TudorzaTM PressairTM […]

Intellectual Property - June 27, 2014

Orexo commences patent infringement litigation against Actavis

Orexo has filed a patent infringement action in the US District Court for the District of Delaware, against Actavis Elizabeth LLC and its parent company Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application (“ANDA”) filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Orexo’s patented […]

Acquisition - February 18, 2014

Actavis to Buy Forest Labs

Actavis PLC plans to buy Forest Laboratories Inc. for about $25 billion. “With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development, and – most important – the ability to drive sustainable […]

Acquisition - June 7, 2013

Enzymatica signs agreement with Actavis

Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme Mouth Spray, on the Nordic market. Under the agreement, the product will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Actavis […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.